Literature DB >> 8640452

Interleukin-8 inhibits non-small cell lung cancer proliferation: a possible role for regulation of tumor growth by autocrine and paracrine pathways.

J Wang1, M Huang, P Lee, K Komanduri, S Sharma, G Chen, S M Dubinett.   

Abstract

Interleukin-8 (IL-8) is an 8 kD chemokine and angiogenic factor produced by alveolar macrophages, endothelial cells, monocytes, fibroblasts, T lymphocytes, and epithelial cells in response to a variety of stimuli, including LPS, TNF-alpha, IL-1, IL-7, and hypoxia. Pulmonary tumors produce a variety of growth factors and cytokines that may act in both autocrine and paracrine fashion. A549, a well-characterized human lung adenocarcinoma line, was cloned for different levels of IL-8 production by limiting dilution. Clone 3B4 produced 361 +/- 73 pg/ml, and clone 2B2 produced 7818 +/- 614 pg/ml of IL-8 (p = 0.003). Clone 3B4 proliferated at 1.7 times the rate of 2B2. Anti-IL-8 reversed the decrement in proliferation of clone 2B2 by 50%, but recombinant IL-8 decreased the proliferation of 3B4 by 40-55% compared with control. In addition to A549, three other non-small cell lung cancer (NSCLC) lines showed significantly decreased proliferation in response to exogenous recombinant IL-8 (5-30 ng/ml; p < 0.05). These findings suggest that in addition to its chemotactic and angiogenic activities, IL-8 may inhibit lung tumor proliferation by both autocrine and paracrine pathways.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8640452     DOI: 10.1089/jir.1996.16.53

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  11 in total

1.  Biologically active neutrophil chemokine pattern in tonsillitis.

Authors:  C Rudack; S Jörg; F Sachse
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

2.  Predictive and prognostic value of LPS-stimulated cytokine secretion in metastatic non-small cell lung cancer.

Authors:  P J Vlachostergios; I Gioulbasanis; S Ghosh; C Tsatsanis; G Papatsibas; A Xyrafas; E Hatzidaki; C Vasiliou; K Kamposioras; S Agelaki; A N Margioris; D Nasi; V Georgoulias; C N Papandreou
Journal:  Clin Transl Oncol       Date:  2013-03-05       Impact factor: 3.405

3.  Epigenetics underpinning the regulation of the CXC (ELR+) chemokines in non-small cell lung cancer.

Authors:  Anne-Marie Baird; Steven G Gray; Kenneth J O'Byrne
Journal:  PLoS One       Date:  2011-01-27       Impact factor: 3.240

4.  Differential diagnosis of lung cancer, its metastasis and chronic obstructive pulmonary disease based on serum Vegf, Il-8 and MMP-9.

Authors:  Murali M S Balla; Sejal Desai; Pallavi Purwar; Amit Kumar; Prashant Bhandarkar; Yogesh K Shejul; C S Pramesh; S Laskar; Badri N Pandey
Journal:  Sci Rep       Date:  2016-11-04       Impact factor: 4.379

5.  Immunosuppressive effect of bladder cancer on function of dendritic cells involving of Jak2/STAT3 pathway.

Authors:  Weigang Xiu; Juan Ma; Ting Lei; Man Zhang; Shangyan Zhou
Journal:  Oncotarget       Date:  2016-09-27

6.  Human papillomavirus up-regulates MMP-2 and MMP-9 expression and activity by inducing interleukin-8 in lung adenocarcinomas.

Authors:  Ming-Yuh Shiau; Li-Ching Fan; Shun-Chun Yang; Chang-Hui Tsao; Huei Lee; Ya-Wen Cheng; Li-Chuan Lai; Yih-Hsin Chang
Journal:  PLoS One       Date:  2013-01-21       Impact factor: 3.240

7.  Interleukin 1beta mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells.

Authors:  Z Culig; A Hobisch; M Herold; A Hittmair; M Thurnher; I E Eder; M V Cronauer; C Rieser; R Ramoner; G Bartsch; H Klocker; G Konwalinka
Journal:  Br J Cancer       Date:  1998-10       Impact factor: 7.640

8.  Interleukin-8/CXCL8 is a growth factor for human lung cancer cells.

Authors:  Y M Zhu; S J Webster; D Flower; P J Woll
Journal:  Br J Cancer       Date:  2004-11-29       Impact factor: 7.640

9.  Clinicopathological and prognostic significance of interleukin-8 expression and its relationship to KRAS mutation in lung adenocarcinoma.

Authors:  N Sunaga; K Kaira; Y Tomizawa; K Shimizu; H Imai; G Takahashi; S Kakegawa; Y Ohtaki; T Nagashima; N Kasahara; O Kawashima; T Hisada; R Saito; M Yamada
Journal:  Br J Cancer       Date:  2014-02-27       Impact factor: 7.640

10.  Regional expression of CXCL12/CXCR4 in liver and hepatocellular carcinoma and cell-cycle variation during in vitro differentiation.

Authors:  Kenji Shibuta; Masaki Mori; Katsuhiro Shimoda; Hiroshi Inoue; Prasenjit Mitra; Graham F Barnard
Journal:  Jpn J Cancer Res       Date:  2002-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.